Release Date: March 07, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: For the 2025 guidance, how do you see the growth of each component? Is the guidance generally more conservative? A: Mike Lawless, CFO: The guidance reflects growth across our three major product lines: ReWalk, AlterG, and MyoCycles. MyoCycles, being the smallest contributor, will likely show the biggest percentage growth due to an expanded distribution agreement. We expect growth in all three lines, focusing on more profitable and efficient growth.
Q: What impact will the CoreLife partnership have on the workers' compensation segment? A: Larry Jasinski, CEO: The CoreLife partnership provides us with a larger conduit into the workers' compensation market, which is about 6% of all spinal cord injuries. CoreLife can process these efficiently, reducing our expenses and ensuring timely payments.
Q: Will the next-gen ReWalk be introduced this year? A: Larry Jasinski, CEO: Yes, we anticipate the next-gen ReWalk will be on the market this year. The product has completed all testing, and we expect FDA clearance in the first half of the year.
Q: How much of the recent announcements, like CoreLife and MyoCycle, are factored into the revenue guidance? A: Larry Jasinski, CEO: We have factored them in conservatively. CoreLife is a new arrangement, but it has good growth potential. The expanded MyoCycle agreement allows us to sell directly to home users, which is a larger market.
Q: What are the learnings from the Medicare reimbursement cycle, and how does it affect discussions with private payers? A: Mike Lawless, CFO: The Medicare cycle has been longer than expected, but it provides a baseline for private payers. We anticipate CMS will become more efficient, and the commercial side seems to have a shorter path.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.